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Summary The 5T4 oncofetal antigen is a 72 kDa glycoprotein defined by a monoclonal antibody raised
against human placental trophoblast and is expressed in many different carcinomas but detected only at low
levels in some normal epithelia. Immunohistochemical analysis of the patterns of expression in colorectal
carcinomas has indicated a significant association between the presence of the antigen in tumour cells and
metastatic spread. The 5T4 antigen phenotype of 72 colorectal cancers has been compared with the clinical
outcome of the patients in order to assess its relationship with prognosis. Forty per cent of tumours were 5T4
positive; the remainder were either unlabelled or exhibited stroma-associated labelling only. There was a
significant correlation between 5T4 expression in the malignant cells and unfavourable course of disease
(P<0.001). The 5 year survival with 5T4-positive tumours was 22% compared with 75% for patients with
5T4-negative tumours; median survival was 24 versus >90 months respectively. Stratified analysis showed that
5T4 antigen tumour positivity was acting independently of each of stage, site of tumour, age or sex. There
were significant differences in survival for patients with Dukes' B and C stage carcinomas (P = 0.001 and
P = 0.034). The results suggest that in colorectal cancer immunohistochemical assessment of 5T4 expression
may be useful in identifying patients at high risk for tumour recurrence and for whom additional treatment
strategies might be most appropriate.
Colorectal carcinoma is one of the most common malignant
diseases in the Western countries and is a leading cause of
neoplastic mortality (American Cancer Society, 1990; King's
Fund Forum, 1990; Silverberg et al., 1990). In the United
States there are approximately 140,000 new cases per year. In
1989 there were 22,000 deaths from this disease in the UK;
this represents a mortality second only to lung cancer in
males and third after lung and breast cancer in females.
The prognosis for colorectal cancer patients has altered
little in the last 20 years, although recent clinical trials have
indicated beneficial affects of radiotherapy and/or
chemotherapy after surgical resection of the primary tumour
(Laurie et al., 1989; Moertel et al., 1990; Krook et al., 1991).
The identification of patient subgroups at high or low risk of
tumour recurrence following surgery would be of practical
importance given the toxicity, differential efficacy and high
cost of the adjuvant treatment.
Dukes' staging (Dukes, 1932) is still the best available
prognostic indicator and dictates most therapeutic decisions.
However, this classification does not give a complete separa-
tion of good and bad prognosis for the individual patient.
Thus, approximately one-third of patients with a Dukes' B
tumour will die from their disease, while one-third ofpatients
with a Dukes' C tumour will become long-term survivors
(Eisenberg et al., 1982). Hence improved methods for pre-
dicting the likely progression of the disease are clearly
required. Such methods may permit the selection of patients
for adjuvant therapy and could influence surgical strategies.
Recent studies have indicated that tumour cell DNA con-
tent and cell proliferation measured by flow cytometry can be
independent prognostic indicators (Matturri et al., 1991; Wit-
zig et al., 1991; Tomoda et al., 1993). Also, initial investi-
gations have suggested a relationship between a number of
genetic changes and poor prognosis for colorectal cancer
patients. Kern et al. (1989) demonstrated a correlation
between distant metastases and deletion of the short arm of
chromosome 17 (which contains the p53 locus) and the long
arm of chromosome 18 (which contains the DCC locus), as
well as high fractional allelic loss (see also Vogelstein et al.,
1989). A relationship between the loss of 18q and decreased
survival has also been shown by O'Connell et al. (1992),
although in this work loss of 17p appeared not to affect
survival. Further work is still required to establish which of
these genetic changes could be useful as prognostic
indicators, and the techniques used are not easily performed
in the clinical setting. An immunologically defined prognostic
marker used in immunohistochemistry would be potentially
advantageous.
A monoclonal antibody 5T4 has been isolated which
recognizes a novel trophoblast oncofetal antigen that is ex-
pressed by developmental tumours and a variety of other
carcinomas but with limited expression in normal tissues
(Hole & Stern, 1988; 1990; Southall et al., 1990). Up to 85%
of colorectal and 81% of gastric carcinomas express 5T4
antigen, and analysis of the patterns of staining has indicated
a correlation with metastasis (Starzynska et al., 1992). There
are two distinct phenotypes of immunohistochemical labell-
ing: either the malignant cell membranes and surrounding
stroma are positive or reactivity is limited to the stroma
adjacent to the tumour. The 5T4-positive staining of malig-
nant cells is more frequent in tumours from patients presen-
ting with lymph node or distant metastases, while 5T4-
negative neoplasms surrounded by positive-staining stroma
are usually from patients with localised disease. This associa-
tion is significant when comparing the frequency of tumour-
positive labelling vs stroma-positive or -negative tumours in
colorectal tumours (P<0.001) and more recently in gastric
tumours (n = 42; P = 0.026).
This study presents follow-up data from the same colorec-
tal cancer patients and evaluates tumour expression of 5T4
antigen as a prognostic indicator for continuing survival 5
years after the original surgery.
Materials and methods
Patients
Seventy-two patients treated by surgical resection of colorec-
tal cancer at different departments of surgery in Manchester,
UK, during 1985-87 and whose tumours were typed for 5T4
antigen expression (Starzynska et al., 1992) were included in
this study. Only two patients received chemotherapy and one
chemoradiotherapy following surgery. The patients' age, sex
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and survival status and their tumours' stage, site, grade and
time of recurrence were recorded. The stage groups were
made according to the criteria of Dukes with modification by
Turnbull et al. (1967). In three patients, tumour resection
was incomplete and in one patient follow-up data were
unavailable, so these patients were excluded from the
analysis. For the 68 patients analysed, the median age was 65
years (range 35-90), and 42 (62%) were male. Eight, 30, 21
and nine carcinomas were Dukes' stage A, B, C and D
respectively. Forty-two tumours were located in the rectum;
nine in the sigmoid; four, two and four in the descending,
transverse and ascending colon respectively; and seven in the
caecum. For further analysis these were divided into rectum
and colon lesions. The colorectal tumours were
predominantly moderately differentiated (46) or well
differentiated (18); only four tumours were poorly
differentiated. The mean time of follow-up for patients still
alive was 68.5 months (the minimum being 5 years). The nine
patients with Dukes' stage D disease were excluded from the
survival analysis.
Immunohistochemistry
Tumour samples were obtained at surgery and the tissue was
immediately embedded in OCT compound, frozen in liquid
nitrogen and subsequently stored at - 70°C. A three-stage
immunoperoxidase technique was used to detect 5T4 antigen
as previously described (Starzynska et al., 1992). Briefly,
slides were incubated sequentially with 5T4 monoclonal
antibody diluted 1:20 for 1 h, biotinylated rabbit anti-mouse
antibodies (Dako) diluted 1:400 for 30 min and strep-
tavidin-horseradish peroxidase (HRP)-conjugated reagent
diluted 1:800 for 30min. Peroxidase was visualised using a
solution of diaminobenzidine tetrahydrochloride (DAB,
Sigma) in Tris-buffered saline (TBS) containing 0.03% hyd-
rogen peroxide. When tumour cells were labelled for 5T4
antigen, there was reactivity in all or nearly all malignant
cells as evidenced by congruency with cytokeratin labelling.
The cellular location appeared mostly membranous. In 11
tumours there was focal reactivity. Tumours were scored by
a single observer (T. Starzynska) and graded as 5T4 positive
if any malignant cells exhibited such membranous staining.
The distinction between tumour and stromal only or negative
labelling was obvious.
Statistical analysis
The disease-free time was defined as the time to the clinical
appearance of local recurrence, metastatic disease or death
from cancer-related causes. The survival time was defined as
the time to cancer-related death. Three patients with incom-
plete tumour resection and all Dukes' stage D patients were
omitted from survival analysis. All patients with stage A, B
and C included in the survival analysis had a curative resec-
tion (as estimated by the surgeon and pathologist). There
were four non-cancer deaths which were accounted for by the
analysis. Statistical analysis of survival or disease-free time
was performed using the log-rank method (Peto et al., 1976,
1977). The presence of 5T4 antigen in tumour cells was
compared with tumour stage, grade, site, patients' age and
sex by Fischer's exact test with a significance level of
P<0.05. Age was analysed as two or four groups split by
the median or quartile values. In order to test that 5T4 was
acting as an independent prognostic indicator, stratified log-
rank analyses were performed, stratifying the data by each of
the other variables in turn.
Results
Figure 1 illustrates the patterns of 5T4 antigen labelling
detected by immunohistochemistry in cryostat sections of
colorectal carcinomas. Table I summarises the 5T4 antigen
expression in the colorectal cancers of the patients analysed
in this study. There is a significant correlation between 5T4
Figure 1 Immunohistochemical labelling patterns of 5T4 antigen
in colorectal carcinomas: a, stroma positive, tumour negative
(x 120); b, tumour and stroma positive (x 300); c, focal tumour
labelling (x 300).
antigen expression by malignant colorectal cells and modified
Dukes' stage (P = 0.001), but not with age, sex, tumour site
or grade. Figure 2 shows the overall disease-free interval and
survival curves for the 5T4-positive and -negative groups.
The difference is highly significant (n = 59, XI2 = 19.8,
P<0.001), with 75% of 5T4-negative patients surviving 5
years compared with only 22% of the 5T4-positive group. In
total, there were 8/38 cancer-related deaths in the 5T4-
negative group and 15/21 in the positive group. There are
significant differences in the disease-free interval and survival
and the four pathological stages. For the different Dukes'
stages the 5 year survivals are as follows: stage B, 73%; and
stage C, 30% (n= 59, XI2= 15.4, P<0.001); there are too
few Duke's A tumours for separate analysis (n = 8). There
were significant differences in survival between patients older
or younger than 65 years (n = 57, x,2= 10.0, P = 0.002).
There were no significant differences in disease-free interval
or overall survival between males and females or between
tumour sites or grades. The three patients who received
chemotherapy following surgery were not long-term sur-
vivors. Stratified analysis showed that 5T4 was acting
independently of each of stage, site of tumour, age or sex.A NOVEL PROGNOSTIC MARKER FOR COLORECTAL CANCER 901
Table I 5T4 antigen expression in colorectal tumour cells vs clinical
pathological features
ST4 positive
Clinicopathological finding Number examined (%)
Agea,b
<65 33 13 (39%)
>65 33 15 (45%)
Sexb
Male- 42 17 (40%)
Female 26 11 (42%)
Siteb
Rectum 42 15 (37%)
Colon 26 13 (15%)
Histologyb
Well differentiated 18 7 (39%)
Moderately differentiated 46 21 (46%)
Poorly differentiated 4 0 (0%)
Dukes' stagec
A 8 2 (25%)
B 30 6 (20%)
C 21 13 (62%)
D 9 7 (78%)
aTwo patient ages unknown.
CStatistically significant (P = 0.001).
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For example, Figure 3 shows the survival curves for the
patients with Dukes' stage B and C and, although the
numbers are small, there are significant differences in survival
between 5T4-positive and -negative patients in both the
subsets (P = 0.001 and P = 0.034 respectively). The full log-
rank analysis stratified by stage shows a highly significant
difference in survival between 5T4-positive and -negative
patients after allowing for the effect of stage (n = 59,
Xi2= 9.1, P = 0.003).
Time (months)
Figure 2 Tumour 5T4 antigen-positive (n = 21) or -negative
(n = 38) tumour expression in relation to survival in 68 colorectal
cancer patients.
Stage B
Discussion
The principal finding of this study is that in colorectal cancer
the expression of 5T4 antigen in malignant cells is associated
with poorer long-term survival. To be useful, the 5T4 marker
must reflect tumour behaviour in a significant and reproduci-
ble way. Seventy-eight per cent of patients with 5T4-positive
tumours died of cancer within 5 years of 'curative' resectional
surgery. The four long-term survivors are 'exceptions' that
might be resolved with longer follow-up. For example, in a
study of 1,704 cases of colorectal carcinoma by Eisenberg et
al. (1982), the proportions ofpatients with Dukes' B tumours
surviving at 5 and 10 years were 74.4% and 65.2% respect-
ively, and with Duke's C tumours 37.3% and 28.8% respect-
ively.
There are other factors which may also influence the
patients' outcome. For example, some 15% of the colorectal
cancers exhibited focal reactivity, with areas of 5T4-positive
and -negative tumour cells seen in the same section (Figure
1c; see also Starzynska et al., 1992). If the acquisition of the
tumour cell-associated 5T4 antigen labelling is a reflection of
the multistep natural history of colorectal cancer, then such
heterogeneity may be an additional consideration when asses-
sing prognosis. Indeed, one of the 5T4-positive long-term
survivor's tumour cells exhibited focal expression.
Heterogeneity of tumour expression might also contribute to
misassignment of 5T4-negative tumours because of
unrepresentative sampling of the tumour biopsy for
immunohistochemistry. This might account for the relatively
short survival ofeight patients with 5T4-negative carcinomas.
Clearly, there are a number of clinical, pathological and
genetic variables which must interact in the natural history of
colorectal cancer (Eisenberg et al., 1982; Fearon & Vogel-
stein, 1990; Ponz de Leon et al., 1992). Nevertheless, our
data suggest that the 5T4 marker is an indicator ofprognosis
which acts independently of Dukes' stage and the other
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Figure 3 Tumour 5T4 antigen labelling in Dukes' stage B or C
patients. The broken line shows the overall survival of patients of
either Dukes' stage B or C and the solid lines the survival of
5T4-positive or -negative subgroups (numbers of patients in
brackets).
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factors examined. Overall there were 21/51 cancer-related
deaths in the Dukes' B and C groups within 5 years, includ-
ing 15/19 patients with 5T4-positive tumours. It appears that
the 5T4 marker could be of practical use in predicting clinical
outcome for individuals with uncertain prognosis. It will be
important to confirm and extend these observations in a
larger prospective study including the antigen status of both
primary and secondary tumour cells.
It is not known what accounts for the different patterns of
5T4 antigen labelling seen in colorectal tumours. It is possi-
ble that the various phenotypes might reflect quantitative or
qualitative differences in expression in relation to malig-
nancy. The original rationale for defining such an oncofetal
antigen was that it may have properties that function to
protect the semiallogeneic fetus from immunological rejection
and which allow tumour cells to evade host immunity. Alter-
natively, the 5T4 surface molecules may function to promote
cellular adhesion, invasion or growth by acting as a specific
ligand receptor. If the function of the 5T4 molecules includes
facilitation of cell movement, then the low levels of expres-
sion seen in some of the basal epithelium may indicate a role
in cell migration in intestinal differentiation processes. A
novel cDNA encoding the core protein of the 5T4 antigen
has now been isolated (Myers et al., 1994), which will allow
investigation of functional aspects of 5T4 tumour expression.
Clinical studies indicate that adjuvant chemotherapy with
5-fluorouracil either alone or in combination with levamisole
may reduce the recurrence rate for patients with resected
colorectal carcinoma of Dukes' stage B and C (Laurie et al.,
1989; Moertel et al., 1990). However, only 30-40% of
patients benefit from such treatment. Our results suggest that
immunohistochemical detection of 5T4 oncofetal antigen may
provide additional prognostic discrimination and thus be
helpful in identifying patients at high risk of recurrence who
would benefit most from adjuvant therapy. Conversely,
patients at low risk could avoid unnecessary toxicity.
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